Pharmaceuticals News and Research

RSS

Watson introduces Amethia Lo and ethinyl estradiol tablets

Watson Pharmaceuticals, Inc. today announced that under a settlement with Teva Women's Health, Watson has launched Amethia Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE.

8 Dec 2011

Senators say burden on Express Scripts and Medco to show merger would benefit consumers, competition

Sen. Herb Kohl on Tuesday told Express Scripts and Medco executives that the burden was "squarely" on them to show that their proposed $29 billion merger would benefit consumers and competition, not just the corporate bottom line.

8 Dec 2011

Alzheimer’s vaccine cures memory of mice

A vaccine that slows the progression of Alzheimer’s disease and other types of dementia has been developed by researchers at the University of Sydney’s Brain and Mind Research Institute (BMRI).

7 Dec 2011

Merck, PATH form partnership to fight causes of maternal mortality

Pharmaceutical company Merck (MSD) announced Monday it has "awarded a grant to PATH, a global health nonprofit, to identify game-changing technologies with the potential to save the lives of women during pregnancy and childbirth in low-resource settings," according to a Merck press release.

7 Dec 2011

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

Future of drug discovery and development to be highlighted at 2011 BPS Winter Meeting

The future of drug discovery and development at the bench and in the boardroom will be highlighted at a major international pharmacology conference in London, Tuesday 13 to Thursday 15 December.

7 Dec 2011

INT-777 shows promise against metabolic syndrome

Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation.

7 Dec 2011

Ranbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd., has launched an authorized generic version of Caduet in the U.S. market, as part of an agreement with Pfizer Inc.

6 Dec 2011

Albert Einstein College of Medicine and Montefiore establish Office of Clinical trials

Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University have established an Office of Clinical Trials (OCT) to bring new therapies more rapidly to patients through the facilitation of efficient, compliant and timely conduct and management of clinical studies.

6 Dec 2011

GE Healthcare, UCSF collaborate for cord blood project

UCSF and the Cell Technologies business of GE Healthcare Life Sciences have begun a unique collaboration aimed at overcoming the lack of blood-forming stem cells available to patients suffering from life-threatening diseases such as lymphoma, myeloma, leukemia or sickle cell anemia.

6 Dec 2011

MorphoSys unveils next-generation antibody technology Ylanthia

MorphoSys AG today unveiled its next-generation antibody technology Ylanthia®. The technology was presented to an audience of specialists at the 2011 Antibody Engineering and Antibody Therapeutics Conference in San Diego. MorphoSys expects Ylanthia to set new standards for therapeutic antibody generation in the pharmaceutical industry over the next decade and beyond. Commercial application will commence in 2012.

6 Dec 2011

EMBL-EBI, BBSRC welcome UK funding announcement on behalf of life science community

The European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) and the Biotechnology and Biological Sciences Research Council (BBSRC) warmly welcome today's announcement from the UK Government of a £75 million commitment from the Department for Business, Innovation and Skills' Large Facilities Capital Fund (LFCF) for the ELIXIR research infrastructure.

6 Dec 2011

Bold move by Astra Zeneca to share 22 early stage potential drugs with MRC

Drug maker AstraZeneca will be sharing 22 of its early-stage research compounds with the Medical Research Council as part of a make over of life sciences research. This would speed up patients’ access to breakthrough drugs and arrest the decline of research and development in the UK.

6 Dec 2011

Cameron says all NHS patients should share their medical data for research

According to British Prime Minister David Cameron, every NHS patient should be a “research patient” with their medical details “opened up” to private healthcare firms. The PM announced that all those who use the NHS in England will be helping in the fight against disease by helping advance research. He hopes the result will be that patients get faster access to new treatments and Britain's life sciences sector will become a world leader.

6 Dec 2011

Roundup: Calif. to drop hospital report cards; Getting a doctor in N.Y. may depend on your neighborhood

The project was considered a pioneering effort when it started in 2004, but Jan Emerson-Shea, a spokesperson for the California Hospital Association, says the report cards have outlived their usefulness. "Today there are numerous places consumers can get information on the quality of care delivered by hospitals," Emerson-Shea says.

6 Dec 2011

Biogen, Samsung partner to develop and market biosimilars

Samsung and Biogen Idec today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars. Samsung will take a leading role in the joint venture, with Biogen Idec contributing its expertise in protein engineering and biologics manufacturing.

5 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Wolters Kluwer Health announces acquisition of STM journal publisher in India, Medknow

Wolters Kluwer Health today announced that it has acquired Medknow PVT Ltd., a leading Scientific, Technical & Medical (STM) journal publishing operation headquartered in Mumbai, India and one of the largest open access publishers in the world.

5 Dec 2011

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

5 Dec 2011